The Valley Desk

NCT05625399 · Interventional trial

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Overall registry status Active not recruiting

Phase 3

Conditions Melanoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov